Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

达帕格列嗪 医学 血糖性 安慰剂 二甲双胍 餐后 低血糖 2型糖尿病 内科学 糖尿病 胰岛素 糖化血红素 不利影响 随机对照试验 泌尿系统 内分泌学 胃肠病学 泌尿科 替代医学 病理
作者
Robert R. Henry,Poul Strange,Rong Zhou,Jeremy Pettus,Leon Shi,Sergey B. Zhuplatov,Traci A. Mansfield,David J. Klein,Arie Katz
出处
期刊:Diabetes Technology & Therapeutics [Mary Ann Liebert, Inc.]
卷期号:20 (11): 715-724 被引量:63
标识
DOI:10.1089/dia.2018.0052
摘要

Background: Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM). Methods: This randomized double-blind placebo-controlled multicenter parallel-design 4-week study compared dapagliflozin (10 mg/d; n = 50) with placebo (n = 50) in adult patients with T2D uncontrolled (HbA1c 7.5%–10.5%) on either stable doses of metformin monotherapy (≥1500 mg/d) or insulin (≥30 U/d with or without up to two oral antidiabetes drugs). CGM was used to measure 24-h glycemic profiles for 7 days pretreatment and during week 4 of treatment. The primary outcome was change from baseline in 24-h mean glucose (MG) at week 4. Results: The 24-h MG decreased 18.2 mg/dL with dapagliflozin and increased 5.8 mg/dL with placebo (P < 0.001). The proportion of time spent in the target glucose range (70–180 mg/dL) increased significantly with dapagliflozin versus placebo (69.6% vs. 52.9%; P < 0.001), with a small (0.3%) increase in time spent in the hypoglycemic range (<70 mg/dL), driven by those on background insulin therapy. Dapagliflozin reduced postprandial glucose and significantly decreased overall glucose variability. Few events of symptomatic hypoglycemia occurred. The most common adverse event was urinary tract infection (6% in each treatment arm). Conclusions: Compared with placebo, dapagliflozin improved measures of glycemic control and variability as assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than those receiving basal insulin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于彦祖应助DZQ采纳,获得30
刚刚
64658应助sh采纳,获得50
刚刚
May完成签到 ,获得积分20
1秒前
1秒前
1秒前
华仔应助Xxiao采纳,获得10
1秒前
1秒前
datang完成签到,获得积分10
2秒前
王鹏飞应助朝气采纳,获得10
2秒前
SRJ发布了新的文献求助30
3秒前
3秒前
mogugu完成签到,获得积分10
3秒前
山后别相逢完成签到 ,获得积分10
3秒前
4秒前
山鬼完成签到,获得积分10
4秒前
ZCM发布了新的文献求助10
4秒前
4秒前
搜集达人应助DXXX采纳,获得10
5秒前
李昆朋发布了新的文献求助10
5秒前
djbj2022发布了新的文献求助10
5秒前
Hayat应助跟我说晚安采纳,获得10
5秒前
隐形曼青应助糖醋可乐采纳,获得10
5秒前
大宝完成签到,获得积分10
6秒前
6秒前
雪ノ下詩乃完成签到,获得积分10
6秒前
大力的契完成签到,获得积分10
6秒前
嘟嘟发布了新的文献求助10
6秒前
6秒前
霸气的惜寒完成签到,获得积分10
7秒前
蓬莱山完成签到 ,获得积分10
7秒前
Lucas发布了新的文献求助30
8秒前
zjjcug完成签到,获得积分10
8秒前
9秒前
lin应助米奇采纳,获得10
9秒前
ddd发布了新的文献求助10
9秒前
H71000A完成签到 ,获得积分10
9秒前
木马不旋转完成签到,获得积分10
9秒前
伶俐书雁发布了新的文献求助10
9秒前
ZCM完成签到,获得积分10
9秒前
可爱的函函应助luyjabc采纳,获得30
9秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969322
求助须知:如何正确求助?哪些是违规求助? 3514152
关于积分的说明 11172188
捐赠科研通 3249407
什么是DOI,文献DOI怎么找? 1794832
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804781